Cargando…

Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis

BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Joonho, Kim, Moinay, Song, Sang Woo, Kim, Young-Hoon, Hong, Chang Ki, Kim, Jeong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819464/
https://www.ncbi.nlm.nih.gov/pubmed/35118844
http://dx.doi.org/10.14791/btrt.2022.10.e30
_version_ 1784646068222296064
author Byun, Joonho
Kim, Moinay
Song, Sang Woo
Kim, Young-Hoon
Hong, Chang Ki
Kim, Jeong Hoon
author_facet Byun, Joonho
Kim, Moinay
Song, Sang Woo
Kim, Young-Hoon
Hong, Chang Ki
Kim, Jeong Hoon
author_sort Byun, Joonho
collection PubMed
description BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN). RESULTS: There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later. CONCLUSION: EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols.
format Online
Article
Text
id pubmed-8819464
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology
record_format MEDLINE/PubMed
spelling pubmed-88194642022-02-15 Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis Byun, Joonho Kim, Moinay Song, Sang Woo Kim, Young-Hoon Hong, Chang Ki Kim, Jeong Hoon Brain Tumor Res Treat Original Article BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN). RESULTS: There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later. CONCLUSION: EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols. The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2022-01 2022-01-28 /pmc/articles/PMC8819464/ /pubmed/35118844 http://dx.doi.org/10.14791/btrt.2022.10.e30 Text en Copyright © 2022 The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology, and The Korean Society for Pediatric Neuro-Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Byun, Joonho
Kim, Moinay
Song, Sang Woo
Kim, Young-Hoon
Hong, Chang Ki
Kim, Jeong Hoon
Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title_full Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title_fullStr Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title_full_unstemmed Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title_short Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
title_sort extraventricular neurocytoma: clinical investigation of heterogenous prognosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819464/
https://www.ncbi.nlm.nih.gov/pubmed/35118844
http://dx.doi.org/10.14791/btrt.2022.10.e30
work_keys_str_mv AT byunjoonho extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis
AT kimmoinay extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis
AT songsangwoo extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis
AT kimyounghoon extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis
AT hongchangki extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis
AT kimjeonghoon extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis